Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus. 2018

Yuanmei Zhu, and Xiujuan Zhang, and Xiaohui Ding, and Huihui Chong, and Sheng Cui, and Jinsheng He, and Xinquan Wang, and Yuxian He
From the MOH Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.

Enfuvirtide (T20) is the only viral fusion inhibitor approved for clinical use, but it has relatively weak anti-HIV activity and easily induces drug resistance. In succession to T20, T1249 has been designed as a 39-mer peptide composed of amino acid sequences derived from HIV-1, HIV-2, and simian immunodeficiency virus (SIV); however, its development has been suspended due to formulation difficulties. We recently developed a T20-based lipopeptide (LP-40) showing greatly improved pharmaceutical properties. Here, we generated a T1249-based lipopeptide, termed LP-46, by replacing its C-terminal tryptophan-rich sequence with fatty acid. As compared with T20, T1249, and LP-40, the truncated LP-46 (31-mer) had dramatically increased activities in inhibiting a large panel of HIV-1 subtypes, with IC50 values approaching low picomolar concentrations. Also, LP-46 was an exceptionally potent inhibitor against HIV-2, SIV, and T20-resistant variants, and it displayed obvious synergistic effects with LP-40. Furthermore, we showed that LP-46 had increased helical stability and binding affinity with the target site. The crystal structure of LP-46 in complex with a target surrogate revealed its critical binding motifs underlying the mechanism of action. Interestingly, it was found that the introduced pocket-binding domain in LP-46 did not interact with the gp41 pocket as expected; instead, it adopted a mode similar to that of LP-40. Therefore, our studies have provided an exceptionally potent and broad fusion inhibitor for developing new anti-HIV drugs, which can also serve as a tool to exploit the mechanisms of viral fusion and inhibition.

UI MeSH Term Description Entries
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077560 Enfuvirtide A synthetic 36-amino acid peptide that corresponds to the heptad repeat sequence of HIV-1 gp41. It blocks HIV cell fusion and viral entry and is used with other anti-retrovirals for combination therapy of HIV INFECTIONS and AIDS. DP 178,DP-178,DP178,Fuzeon,Pentafuside,Peptide T20,T20 Peptide,T20, Peptide
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015498 HIV-2 An HIV species related to HIV-1 but carrying different antigenic components and with differing nucleic acid composition. It shares serologic reactivity and sequence homology with the simian Lentivirus SIMIAN IMMUNODEFICIENCY VIRUS and infects only T4-lymphocytes expressing the CD4 phenotypic marker. HTLV-IV,Human T-Lymphotropic Virus Type IV,Human immunodeficiency virus 2,LAV-2,HIV-II,Human Immunodeficiency Virus Type 2,Human T Lymphotropic Virus Type IV,Immunodeficiency Virus Type 2, Human,SBL-6669
D044966 Anti-Retroviral Agents Agents used to treat RETROVIRIDAE INFECTIONS. Antiretroviral Agent,Antiretroviral Agents,Agent, Antiretroviral,Agents, Anti-Retroviral,Agents, Antiretroviral,Anti Retroviral Agents
D053586 Virus Internalization The entering of cells by viruses following VIRUS ATTACHMENT. This is achieved by ENDOCYTOSIS, by translocation of the whole virus across the cell membrane, by direct MEMBRANE FUSION of the viral membrane with the CELL MEMBRANE, or by fusion of the membrane of infected cells with the membrane of non-infected cells causing SYNCYTIA to be formed. Viral Entry,Viral Internalization,Viral Membrane Fusion,Virus Entry,Virus Membrane Fusion,Entry, Viral,Entry, Virus,Fusion, Viral Membrane,Internalization, Viral,Internalization, Virus,Membrane Fusion, Viral
D055666 Lipopeptides Compounds consisting of a short peptide chain conjugated with an acyl chain. Lipopeptide,Anionic Lipopeptide,Anionic Lipopeptides,Cationic Lipopeptide,Cationic Lipopeptides,Lipopeptide, Anionic,Lipopeptide, Cationic,Lipopeptides, Anionic,Lipopeptides, Cationic

Related Publications

Yuanmei Zhu, and Xiujuan Zhang, and Xiaohui Ding, and Huihui Chong, and Sheng Cui, and Jinsheng He, and Xinquan Wang, and Yuxian He
January 2017, Journal of virology,
Yuanmei Zhu, and Xiujuan Zhang, and Xiaohui Ding, and Huihui Chong, and Sheng Cui, and Jinsheng He, and Xinquan Wang, and Yuxian He
April 2013, AIDS (London, England),
Yuanmei Zhu, and Xiujuan Zhang, and Xiaohui Ding, and Huihui Chong, and Sheng Cui, and Jinsheng He, and Xinquan Wang, and Yuxian He
October 2018, Journal of virology,
Yuanmei Zhu, and Xiujuan Zhang, and Xiaohui Ding, and Huihui Chong, and Sheng Cui, and Jinsheng He, and Xinquan Wang, and Yuxian He
December 2021, Emerging microbes & infections,
Yuanmei Zhu, and Xiujuan Zhang, and Xiaohui Ding, and Huihui Chong, and Sheng Cui, and Jinsheng He, and Xinquan Wang, and Yuxian He
November 2019, Journal of virology,
Yuanmei Zhu, and Xiujuan Zhang, and Xiaohui Ding, and Huihui Chong, and Sheng Cui, and Jinsheng He, and Xinquan Wang, and Yuxian He
July 2020, Journal of virology,
Yuanmei Zhu, and Xiujuan Zhang, and Xiaohui Ding, and Huihui Chong, and Sheng Cui, and Jinsheng He, and Xinquan Wang, and Yuxian He
October 2010, Molecular aspects of medicine,
Yuanmei Zhu, and Xiujuan Zhang, and Xiaohui Ding, and Huihui Chong, and Sheng Cui, and Jinsheng He, and Xinquan Wang, and Yuxian He
August 2012, The Journal of biological chemistry,
Yuanmei Zhu, and Xiujuan Zhang, and Xiaohui Ding, and Huihui Chong, and Sheng Cui, and Jinsheng He, and Xinquan Wang, and Yuxian He
September 1988, Proceedings of the National Academy of Sciences of the United States of America,
Yuanmei Zhu, and Xiujuan Zhang, and Xiaohui Ding, and Huihui Chong, and Sheng Cui, and Jinsheng He, and Xinquan Wang, and Yuxian He
June 2017, Nature communications,
Copied contents to your clipboard!